Independent Financial Information Made Easy
The development of Artificial Intelligence (AI) is modifying the way investments are evaluated. We programmed an artificial intelligence (A.I.) to summarize the whole internet. Whether you’re trying to make money investing online, making financial decisions or just getting informed about Wall Street, this page is a way to get informed without reading hundred of pages. Our stock market summary graphs are produced using machine learning, an unbiased view to capture what internet is saying. Usually, the AI reads several hundred pages and summarize it to a short text and several charts.
Open: 0.24 Close: 0.23 Change: -0.01
Are looking for the most relevant information about Synaptogenix? Investor spend a lot of time searching for information to make investment decisions in Synaptogenix. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Synaptogenix are: show, cognitive, decline, trial, Synaptogenix, Inc, tenmonth, and the most common words in the summary are: synaptogenix, company, stock, snpx, price, new, zacks, . One of the sentences in the summary was: Patients with severe Alzheimers Disease (AD) showed no. Other searches related to this term …
Bryostatin-1 for later-stage patients would be complementary to the early-stage AD drugs. Bryostin-1 would be a full range of treatment options..
Synaptogenix, Inc. showed no cognitive decline throughout a ten-month trial while being treated with Bryostatin-1. Patients with severe Alzheimers Disease (AD) showed no. cognitive decline in a ten month trial.
Synaptogenix, Inc. showed no cognitive decline throughout a ten-month trial while being treated with Bryostatin-1. Patients with severe Alzheimers Disease (AD) showed no. cognitive decline in a ten month trial.
" Emerging biotech, Synaptogenix Inc., develops therapeutics for neurodegenerative disorders. Bryostatin-1 for later-stage patients would be complementary to the early-stage AD drugs in providing a full range of treatment options."
How much time have you spent trying to decide whether investing in Synaptogenix? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Synaptogenix are: show, cognitive, decline, trial, Synaptogenix, Inc, tenmonth, and the most common words in the summary are: synaptogenix, company, stock, snpx, price, new, zacks, . One of the sentences in the summary was: Patients with severe Alzheimers Disease (AD) showed no. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #synaptogenix #company #stock #snpx #price #new #zacks.
Read more →Open: 0.24 Close: 0.23 Change: -0.01
Read more →Open: 0.35 Close: 0.31 Change: -0.04
Read more →